1 Top Pharma Growth Stock to Buy Today and Hold Forever
If, like many other investors, you've written off big pharma stocks because of their reputation for being slow-growing giants, Vertex Pharmaceuticals (NASDAQ: VRTX) might be the breath of fresh air you're looking for now. Far from being a sloth, this stock is up 91% in the past five years, topping the market's growth of 70%, and it has a few catalysts to grow further, and soon. Let's see why.
The company's bedrock are its four therapies for cystic fibrosis (CF), a rare hereditary lung disease. In 2022, those medicines sold for more than $8.9 billion, generating the business $3.9 billion in free cash flow in the process. It's also expecting to bring in up to $9.8 billion in sales for this year, which is a testament to how effective it is at squeezing more and more growth out of the market for CF therapies.
Because CF is a chronic and as-of-yet incurable condition, people need to keep taking the drugs for their entire lifespan. While Vertex's entries aren't the only therapies for CF, they are the only ones that can treat the root cause of the disease rather than the symptoms alone, which puts them in a privileged position in the market. And that's a big part of the reason why Vertex's annual top line grew by 636% over the last 10 years.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Community zeigt großes Interesse an Vertex Pharmaceuticals Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 459 € für Vertex Pharmaceuticals Inc. impliziert eine leichte Steigerung gegenüber dem aktuellen Kurs von 433.75 €.
